Canavan Disease

A rare, autosomal recessive leukodystrophy caused by mutations in the ASPA gene, encoding aspartoacylase. This enzyme breaks down N acetylaspartate within the central nervous system. Loss of function causes pathological accumulation of this compound and severe, progressive spongiform degeneration of the white matter.

It presents classically in early infancy with progressive macrocephaly, severe hypotonia progressing to spasticity, and profound developmental impairment.

It is one of the more common leukodystrophies within specific founder populations, particularly individuals of Ashkenazi Jewish ancestry. Carrier screening is often incorporated into the genetic screening panels for this population.

The course is severe, currently incurable, and life limiting, though emerging gene therapy approaches offer potential future promise.

Pathophysiology

• Loss of aspartoacylase activity prevents normal breakdown of N acetylaspartate, a compound produced in substantial quantities within neurons. It accumulates pathologically within the central nervous system.
• Excess N acetylaspartate is believed to disrupt osmotic and metabolic homeostasis within white matter. This produces the pathological hallmark: severe spongiform degeneration (vacuolation and swelling) of myelin and white matter structure.
• White matter involvement is severe and disproportionate, in contrast to relatively preserved neuronal cell bodies within grey matter. This reflects the specific vulnerability of myelin forming oligodendrocytes and surrounding white matter architecture to excess N acetylaspartate.
• It underlies the diffuse leukoencephalopathy pattern seen on neuroimaging.

• The typical early presentation of the classical, severe infantile form is progressive macrocephaly, developing over the first months of life and often apparent by three to six months of age.
• It comes with severe hypotonia, poor head control, and significant developmental delay. Hypotonia contrasts with several other leukodystrophies, which more typically present with early spasticity.
• Progressive neurological deterioration follows over subsequent months. Hypotonia evolves into progressive spasticity.
• Visual impairment reflects optic nerve and visual pathway involvement. Seizures and profound, global developmental impairment also occur.
• The great majority of affected children never achieve independent sitting, walking, or meaningful expressive language, given the severity and rapid progression of the neurodegenerative process.
• Feeding difficulty, with risk of aspiration and growth impairment, is an important complication. In more advanced disease, significant respiratory compromise emerges. Both need proactive management throughout the course.
• The classical, severe infantile form is relentlessly progressive, with survival typically limited to childhood.
• The rate of progression and ultimate survival can show some variability. Rare, milder, later onset phenotypes are also recognised. They are generally associated with less severe mutations that retain some residual enzyme function.

• Urine organic acid analysis showing markedly elevated N acetylaspartate excretion is a valuable, relatively accessible initial diagnostic clue. This metabolite is characteristically and substantially elevated in affected individuals.
• Magnetic resonance spectroscopy, where available, can directly demonstrate elevated N acetylaspartate within brain tissue. It is further supportive, non invasive evidence.
• Conventional magnetic resonance imaging shows diffuse, symmetric white matter signal change. It predominantly and often disproportionately affects the subcortical white matter, in contrast to several other leukodystrophies with a more periventricular pattern.
• Genetic testing for ASPA gene mutations gives definitive confirmation. It is needed for confirming the diagnosis in an affected individual and for accurate genetic counselling and carrier testing of at risk family members.
• Carrier frequency is elevated in specific founder populations, most notably individuals of Ashkenazi Jewish ancestry.
• Carrier screening for Canavan disease is therefore frequently incorporated into preconception or antenatal genetic screening panels offered to individuals of Ashkenazi Jewish ancestry.
• Screening supports informed reproductive decision making. Where relevant, it allows early diagnosis through targeted prenatal testing in identified at risk pregnancies.

• There is no currently established, effective disease modifying or curative treatment for Canavan disease. Management is entirely supportive and palliative, addressing the progressive, severe neurological impairment and its complications.
• Full, multidisciplinary supportive care is the central component of management.
• It includes physiotherapy to manage progressive spasticity and optimise comfort and positioning, and occupational therapy support. Appropriate equipment (specialist seating, mobility support) is provided as functional capacity declines.
• Nutritional support includes consideration of gastrostomy feeding where oral intake becomes inadequate or aspiration risk is significant.
• Seizures are managed proactively with standard antiepileptic medication where they develop.
• Palliative care involvement is appropriate, given the severe, life limiting nature of the classical infantile form. It provides symptom management, family support, and advance care planning discussion.
• Timing and approach to palliative care integration are individualised to the family's wishes and the pace of disease progression in the child.
• Gene therapy aims to deliver a functional copy of the ASPA gene directly to the central nervous system. It has shown promising early results in clinical trials.
• It is a potential future avenue that may substantially alter the currently severe, untreatable natural history. It remains investigational rather than an established, widely available treatment. Ongoing research offers meaningful hope of improved outcomes for affected children and their families.
• Genetic counselling for the family is an essential component of family centred care, given the severe, hereditary nature of this rare condition.
• It covers the autosomal recessive inheritance pattern, recurrence risk for future pregnancies, and reproductive options including prenatal and preimplantation genetic testing.
• It also connects the family to specialist metabolic and genetics services and patient support organisations.